Author

Nermin Samir

h-index 8 View on Semantic Scholar

We have 3 of 26 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Dual inhibitors of CDK2 and TRKA kinases: design, synthesis, antiproliferative activity and molecular modeling of novel pyrazolopyrimidine derivatives

Simultaneous inhibition of CDK2 and TRKA presents a promising therapeutic avenue for cancer treatment, capitalizing on the critical roles of CDK2 in cell cycle regulation and TRKA in tumor cell survival and progression. In continuation of our previous work on dual CDK2/TRKA inhibitors, two series of pyrazolo[1,5-a]pyri...

Mohamed H. Attia, Deena S. Lasheen, Nermin Samir et al. · RSC Advances · 0 citations

Review Open access Jul 2026

FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches

This review analyzes how hinge contacts, back-pocket occupancy, and warhead placement govern activity across wild-type and mutant FLT3, and links binding mode, covalent engagement, and second-target selection to recurrent resistance biology to guide more resilient FLT3-targeted therapies for high-risk AML.

Fatma M Elmenier, Eman M. E. Dokla, Nermin Samir et al. · RSC Advances · 0 citations

Review Open access Jul 2026

Unlocking new antimicrobial leads in the last decade: exploring quinolin-2-one based hybrids' synthesis, action, SAR, and challenges in tackling antimicrobial resistance.

Quinolin-2-one derivatives demonstrated considerable therapeutic promise as versatile antimicrobial scaffolds, but current studies revealed several limitations, including poor aqueous solubility, insufficient preclinical ADMET characterization, and limited in vivo validation.

M. A. Khattab, Sha-Hin I. Mai, A. Taher et al. · Future Medicinal Chemistry · 0 citations